Company Data

UroGen Pharma Ltd.

Ticker
URGN
Current Price
$14.2 -1.8%
Market Cap
$484.5M
Price Target
Refer to Report
Volume
181.0K
52wk Range
$7.75 - $24.13
Advanced Market Data

Overview

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company’s lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Inbox Intel from Channelchek.

Informed investors make more money. And itโ€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
ยฉ 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.